FIBROGEN INC: directors' dealings · United States · SEC (Form 4)

About FIBROGEN INC

FibroGen Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ market in the United States and headquartered in San Francisco, California. Founded in 1993, the company was originally built around expertise in hypoxia biology, fibrosis pathways, and oncology research. Over time, FibroGen has evolved from a broader discovery-stage biotech into a more focused development company, with its value proposition now tied primarily to clinical execution, regulatory outcomes, and balance-sheet management. Historically, FibroGen became best known for roxadustat, an oral HIF prolyl hydroxylase inhibitor developed for anemia-related indications. The company also advanced pamrevlumab, a fully human monoclonal antibody targeting CTGF, and has explored other programs in fibrosis and cancer. More recently, FibroGen has sharpened its strategic focus around FG-3246, a potential first-in-class antibody-drug conjugate targeting CD46 and being developed for metastatic castration-resistant prostate cancer (mCRPC). It is also developing FG-3180, a CD46-targeted PET imaging agent. This concentration on a smaller number of assets reflects a broader portfolio rationalization and a shift toward programs with the clearest near- to medium-term catalysts. From a competitive standpoint, FibroGen operates in highly crowded therapeutic areas, especially oncology and hematology. Its differentiation does not rest on commercial scale, but on scientific novelty, platform know-how, and the ability to generate compelling clinical data. As with many biotech peers, the company’s future economics depend heavily on proof-of-concept results, trial design, partnering optionality, and regulatory milestones rather than steady product-driven cash flows. A major recent development was the sale of FibroGen China to AstraZeneca, announced and completed in 2025. Management framed the transaction as a way to simplify the company, strengthen liquidity, and extend its cash runway into 2027, while keeping strategic rights to roxadustat in the U.S. and other non-excluded markets. FibroGen also pursued a reverse stock split in 2025 to help regain compliance with NASDAQ listing requirements. These actions highlight a company in transition: exiting non-core international complexity, reducing operating costs, and focusing capital on a narrower U.S.-centered development pipeline. For investors, FibroGen remains a high-risk, event-driven biotech story. The investment case is driven by clinical readouts, pipeline execution, and capital structure discipline, with the NASDAQ listing and the United States operating base central to its market profile.